MONITORING FOR CARDIOVASCULAR RISK IN THE OUTPATIENT SETTING IS ESSENTIAL: A CASE REPORT.

2014 ◽  
Vol 25 (4) ◽  
pp. 125
Author(s):  
Brady Tsukamaki ◽  
Tamara Struessel ◽  
Eric E. Sawyer
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Lorenzo Storari ◽  
Valerio Barbari ◽  
Fabrizio Brindisino ◽  
Marco Testa ◽  
Maselli Filippo

Abstract Background Shoulder pain (SP) may originate from both musculoskeletal and visceral conditions. Physiotherapists (PT) may encounter patients with life-threatening pathologies that mimic musculoskeletal pain such as Acute Myocardial Infarction (AMI). A trained PT should be able to distinguish between signs and symptoms of musculoskeletal or visceral origin aimed at performing proper medical referral. Case presentation A 46-y-old male with acute SP lasting from a week was diagnosed with right painful musculoskeletal shoulder syndrome, in two successive examinations by the emergency department physicians. However, after having experienced a shift of the pain on the left side, the patient presented to a PT. The PT recognized the signs and symptoms of visceral pain and referred him to the general practitioner, which identified a cardiac disease. The final diagnosis was acute myocardial infarction. Conclusion This case report highlights the importance of a thorough patient screening examination, especially for patients treated in an outpatient setting, which allow distinguishing between signs and symptoms of musculoskeletal from visceral diseases.


2019 ◽  
Vol 4 (5) ◽  
pp. 234-237 ◽  
Author(s):  
Tariq Azamgarhi ◽  
James Donaldson ◽  
Ashik Shah ◽  
Simon Warren

Abstract. We report a case of an infected massive endoprosthetic replacement treated successfully with 2 stage surgery and off-label dalbavancin. Dalbavancin was used due to a limited number of antimicrobial options that could be administered safely in an outpatient setting and to avoid the need for daily dosing.


2020 ◽  
Vol 44 (3) ◽  
pp. 150-153
Author(s):  
Richard A. Meena ◽  
Melissa N. Warren ◽  
Thomas E. Reeve ◽  
Olamide Alabi

Aortocaval fistula (ACF) is a rare and life-threatening complication associated with rupture of an abdominal aortic aneurysm (rAAA). Early detection and management of ACF’s during surgical repair of rAAAs is recommended to reduce the risk of future aneurysm-related complications, including mortality. There is a paucity of current literature on the natural history of ACFs postendovascular exclusion. We present a case study describing the detection of a persistent ACF by duplex ultrasonography (DU) postendovascular aortic repair (EVAR).


2019 ◽  
Vol 143 (5) ◽  
pp. 481-485
Author(s):  
Eleonora Ghisoni ◽  
Laura Marandino ◽  
Pasquale Lombardi ◽  
Alessandro Bonzano ◽  
Paolo Becco ◽  
...  

Cardiovascular adverse events (CVAEs) are of considerable importance in patients with multiple myeloma (MM), given the significant prevalence of coexisting cardiovascular risk factors and the potential treatment-induced toxicity. Brugada syndrome is a rare cardiological disease responsible for arrhythmia and potentially fatal cardiac arrest. Brugada phenocopies (BrP) are clinical entities which show an identical ECG patterns, but prompt resolution after treatment of the trigger event. A 65-year-old female newly diagnosed MM patient treated with a carfilzomib-based chemotherapy developed a type 1 Brugada ECG pattern during a hospitalization course for sepsis. As fever and the septic event resolved, further ECGs showed no abnormalities and carfilzomib-based treatment could be resumed with no further CVAEs. Though fever-induced BrP is a universally known phenomenon, to our knowledge this is the first case of BrP in a patient with MM during active treatment with carfilzomib.


2018 ◽  
Vol 4 (4) ◽  
pp. 255 ◽  
Author(s):  
Xiulu Ruan, MD ◽  
Riaz Tadia, MD ◽  
Hainan Liu, MS ◽  
John Patrick Couch, MD ◽  
John Keun-Sang Lee, MD, PhD

Background: Intraspinal drug delivery (IDD) therapy has been increasingly employed in patients with intractable, nonmalignant pain. Before implantation of permanent intraspinal pump, an intraspinal opioid screening trial is conducted to demonstrate the efficacy. The patient-controlled continuous epidural opioid infusion trail, performed in an outpatient setting, is widely accepted by many interventional pain specialists.Objective: To report a case of severe edema observed during the continuous epidural hydromorphone infusion trial.Case Report: An otherwise healthy 68-year-old lady with a 5-year history of severe low back pain and bilateral leg pain because of failed back surgery syndrome was referred to our clinic for IDD therapy.A tunneled lumbar epidural catheter was placed at L2- L3 with catheter tip advanced to L1 under fluoroscopic guidance. Satisfactory catheter placement was confirmed by epidurogram. The catheter was then tunneled subcutaneously and connected to a Microject™ patient-controlled epidural analgesia (PCEA) pump (Codman, Raynham, MA). The pump was programmed to deliver hydromorphone (0.1 mg/ml) at basal rate of 0.3 ml/h. The bolus dose was 0.1 ml with a 60-minute lockout interval. The patient was instructed how to operate the infusion pump. During the following infusion trial, she reported satisfactory analgesia (>70 percent pain reduction) and was able to wean off her other systemic opioids. However, she developed diffuse edema and gained over 16 pounds during the 5-day infusion trial. Her edema finally resolved 3-4 days after termination of the epidural infusion.Conclusion: Edema may occur and persist during epidural hydromorphone infusion. This report represents the first case report, to the best of our knowledge, describing severe edema in a patient on continuous epidural hydromorphone administration during an outpatient epidural infusion trial.


2021 ◽  
Vol 4 (1) ◽  
pp. 63-66
Author(s):  
Sanith Cheriyan ◽  
Jacob Jervis-Bardy

The practice of delivering cosmetic injectables in the outpatient setting continues to grow in Australia.1 The increase in demand has seen a dramatic rise in the number of new cosmetic injectable clinics using telehealth prescribing services. Lipodissolve treatment is an example of a non-surgical procedure that aims to improve the appearance of a ‘double chin’ by injection of phosphatidylcholine (PC) and deoxycholic acid (DCA) into submental adipose tissue. We describe a case of an airway complication and hospitalisation secondary to the injection of Lipodissolve in the neck of a 23-year-old female.


Sign in / Sign up

Export Citation Format

Share Document